Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital)

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameAllogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital)

Drug Alias NameAllogenic CD19-targeting CAR-γδT Cell Therapy(PLA General Hospital)

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy +[5]

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesPla General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A